SCN5A and cardiac rhythm disease: This is particularly noteworthy given previous concerns regarding eliglustat’s potential to induce cardiac arrhythmias, primarily based on in vitro studies showing inhibition of key ion channels, including hERG, Nav1.5, and Cav1.2 (7).